関: spirapril hydrochloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/26 18:15:23」(JST)

wiki en

Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ace inhibitor.

Like many ACE inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment.^[1] However, data on its effect upon the renal function are conflicting.^[2]

References

^ Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). "Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.". Scand J Urol Nephrol 33 (1): 57–62. doi:10.1080/003655999750016294. PMID 10100366.
^ Noble S, Sorkin E (1995). "Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.". Drugs 49 (5): 750–66. doi:10.2165/00003495-199549050-00008. PMID 7601014.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 左室肥大および不整脈 left ventricular hypertrophy and arrhythmia
2. 成人の非糖尿病性慢性腎臓病患者に対する降圧療法と病状の進展 antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults

English Journal

Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation.

Hermida RC1, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F.
Chronobiology international.Chronobiol Int.2013 Mar;30(1-2):280-314. doi: 10.3109/07420528.2012.709448. Epub 2012 Oct 19.
Specific features of the 24-h blood pressure (BP) pattern are linked to progressive injury of target tissues and risk of cardiovascular disease (CVD) events. Several studies have consistently shown an association between blunted asleep BP decline and risk of fatal and nonfatal CVD events. Thus, ther
PMID 23077971

Perfusion calorimetry in the characterization of solvates forming isomorphic desolvates.

Baronsky J1, Preu M, Traeubel M, Urbanetz NA.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2011 Sep 18;44(1-2):74-82. doi: 10.1016/j.ejps.2011.06.008. Epub 2011 Jun 25.
In this study, the potential of perfusion calorimetry in the characterization of solvates forming isomorphic desolvates was investigated. Perfusion calorimetry was used to expose different hydrates forming isomorphic desolvates (emodepside hydrates II-IV, erythromycin A dihydrate and spirapril hydro
PMID 21726637

Effect of angiotensin-converting enzyme inhibitor quadropril on dynamic parameters of vascular tone under conditions of NO synthesis blockade in normotensive and spontaneously hypertensive rats.

Sonin DL1, Galagoudza MM, Syrensky AV, Tsyrlin VA.
Bulletin of experimental biology and medicine.Bull Exp Biol Med.2011 Jul;151(3):311-3.
The role of NO in the mechanism of quadropril modulation of the flow-dependent vasodilation was examined in normotensive (Wistar) and spontaneously hypertensive (SHR) rats. The abdominal aorta was cannulated and autoperfused at different volume rates to obtain the pressure-flow curves. In the first
PMID 22451874

Japanese Journal

Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy. Effects on LVH regression and arrhythmogenic propensity

MANOLIS AJ
Am J Hypertens 11, 640-648, 1998
NAID 30008928042

Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats

OLIVETTI G.
J Cardiovasc Pharmacol 21, 362-370, 1993
NAID 80006955607

Related Pictures

★リンクテーブル★

リンク元	「スピラプリル」
拡張検索	「spiraprilat」「spirapril hydrochloride」

「スピラプリル」

Spirapril
Systematic (IUPAC) name
	(8S)-7-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	D;
Legal status	℞ (Prescription only);
Routes of; administration	Oral
Pharmacokinetic data
Bioavailability	50%
Metabolism	converted to spiraprilat
Biological half-life	30 to 35 hours
Excretion	Hepatic and renal
Identifiers
CAS Registry Number	83647-97-6
ATC code	C09AA11
PubChem	CID: 5311447
IUPHAR/BPS	6575
DrugBank	DB01348
ChemSpider	4470933
UNII	96U2K78I3V
KEGG	D08529
ChEMBL	CHEMBL431
Chemical data
Formula	C22H30N2O5S2
Molecular mass	466.616 g/mol
	SMILES O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3 ;
	InChI InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1 ; Key:HRWCVUIFMSZDJS-SZMVWBNQSA-N ;
(what is this?) (verify)